Citadel Advisors
CSBR icon

Citadel Advisors’s Champions Oncology CSBR Stock Holding History

Citadel Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,800
Closed -$116K – 12936
2025
Q2 		$116K Buy
15,800
+1,200
+8% +$8.47K ﹤0.01% 11200
2025
Q1 		$127K Buy
14,600
+8,100
+125% +$82.1K ﹤0.01% 11132
2024
Q4 		$55.7K Buy
+6,500
New +$32.7K ﹤0.01% 12277
2024
Q3 		– Sell
-3,300
Closed -$17.1K – 14353
2024
Q2 		$17.1K Buy
3,300
+700
+27% +$3.41K ﹤0.01% 12768
2024
Q1 		$12.7K Buy
2,600
+1,900
+271% +$11.1K ﹤0.01% 13345
2023
Q4 		$3.79K Sell
700
-500
-42% -$2.79K ﹤0.01% 13558
2023
Q3 		$7.46K Sell
1,200
-6,000
-83% -$37.9K ﹤0.01% 13256
2023
Q2 		$45.3K Buy
7,200
+1,100
+18% +$5.68K ﹤0.01% 11919
2023
Q1 		$24.5K Buy
6,100
+1,600
+36% +$6.84K ﹤0.01% 12908
2022
Q4 		$20.3K Sell
4,500
-179,600
-98% -$1.17M ﹤0.01% 13135
2022
Q3 		$1.38M Sell
184,100
-35,200
-16% -$294K ﹤0.01% 6318
2022
Q2 		$1.77M Buy
219,300
+31,100
+17% +$238K ﹤0.01% 5795
2022
Q1 		$1.53M Buy
+188,200
New +$1.51M ﹤0.01% 6683

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $368M AUM 28.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors's CSBR Position: Q2 2026 in Review

Citadel Advisors opened a new position in Champions Oncology (CSBR) in Q2 2026: 18,295 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #12602 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CSBR as recently as Q3 2025.

Citadel Advisors first reported a position in CSBR in Q3 2016 and has held it in 15 quarters since. The position peaked at $280K in Q3 2022. 28 funds tracked by Wall St. Rank hold CSBR as of Q2 2026.

  • Citadel Advisors held 18,295 shares of Champions Oncology worth $113K as of Q2 2026.
  • Champions Oncology was a new Citadel Advisors position in Q2 2026.
  • Champions Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12602 holding.
  • Citadel Advisors first reported a position in Champions Oncology in Q3 2016 and has held it in 15 quarters since.
  • Citadel Advisors's Champions Oncology position peaked at $280K in Q3 2022.
  • 28 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.